Biotech Stocks: Human Genome dips; Array rockets
April 23, 2010 by biotechcheck.com · Leave a Comment
Biotech Stocks: Human Genome dips; Array rockets
Shares of Human Genome Sciences fell in early trading Tuesday, pushed down by the release of mixed Phase III data for its eagerly-anticipated lupus drug Benlysta.
Read more on Market Watch
D-Pharm Receives Agreement Letter On Special Protocol Assessment For DP-b99 Study – A Pivotal Phase III Trial In Acute …
April 20, 2010 by biotechcheck.com · Leave a Comment
D-Pharm Receives Agreement Letter On Special Protocol Assessment For DP-b99 Study – A Pivotal Phase III Trial In Acute …
D-Pharm Ltd (DPRM: TASE) announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) procedure for a pivotal phase 3 trial (MACSI) of its neuroprotective agent DP-b99 in acute ischemic stroke patients. The SPA agreement letter indicates that “the design and planned analysis of the study adequately address the objectives …
Read more on Medical News Today
Positive Phase III Diabetes Data with Lixisenatide Announced by Zealand Pharma’s Partner sanofi-aventis
April 17, 2010 by biotechcheck.com · Leave a Comment
Positive Phase III Diabetes Data with Lixisenatide Announced by Zealand Pharma’s Partner sanofi-aventis
GLOSTRUP, DENMARK–(Marketwire – 04/15/10) – Copenhagen, 15 April 2010 Announcement no. 3, 2010 Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note today that sanofi-aventis, its partner, has announced the positive results of the first, placebo-controlled study of the GetGoal Phase III clinical trial …
Read more on Marketwire via Yahoo! Finance
Biotech Stocks on the Move
April 13, 2010 by biotechcheck.com · Leave a Comment
* Merriman Curhan Ford 5th Annual Investor Summit * Curis cancer drug in clinical trials * genvec cancer drug enters Phase III * medicinova discusses early test for asthma and MS drugs
Biotech curse strikes again
April 1, 2010 by biotechcheck.com · Leave a Comment
Biotech curse strikes again
Shares in Antisoma, the oncology research company, slumped by 70 per cent after its partner, Swiss company Novartis, cancelled the further development of Antisoma’s ASA404 lung cancer treatment after an interim study of the Phase III ‘Attract-1′ trial showed there would be no positive result.
Read more on Investors Chronicle
